AU Patent

AU2012257785A1 — Intranasal pharmaceutical dosage forms comprising naloxone

Assigned to Euro Celtique SA · Expires 2013-11-28 · 12y expired

What this patent protects

The present invention relates to an intranasal pharmaceutical dosage form comprising a dosing unit comprising naloxone or a pharmaceutically acceptable salt thereof in an amount of equivalent to ≥ 0.5 mg naloxone HCl dissolved in an application fluid of a volume of ≤ 250 µl. Furt…

USPTO Abstract

The present invention relates to an intranasal pharmaceutical dosage form comprising a dosing unit comprising naloxone or a pharmaceutically acceptable salt thereof in an amount of equivalent to ≥ 0.5 mg naloxone HCl dissolved in an application fluid of a volume of ≤ 250 µl. Furthermore, the present invention relates to such an intranasal pharmaceutical dosage form for use in the treatment of opioid overdosing and/or at least one symptom thereof.

Drugs covered by this patent

Patent Metadata

Patent number
AU2012257785A1
Jurisdiction
AU
Classification
—
Expires
2013-11-28
Drug substance claim
No
Drug product claim
No
Assignee
Euro Celtique SA
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.